查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561030

肝素市场规模、份额、成长分析、按类型、按给药途径、按原料、按应用、按最终用户、按地区 - 行业预测，2024-2031 年

Heparin Market Size, Share, Growth Analysis, By Type, By Route of Administration,, By Source, By Application, By End User, By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球肝素市场规模为73.2亿美元，从2023年的75.1亿美元成长到2031年的92.2亿美元，预测期间（2024-2031年）复合年增长率为2.6%，预计将成长至2022年。

2022 年 8 月，FDA核准了Momenta 学名药是与诺华公司学名药部门 Sandoz 合作开发的 Robenox 仿製药。由于技术的改进，M-依诺肝素主要用于大型整形外科手术，例如置换术和膝关节关节重建。肝素研究的最新趋势，特别是开发用于化疗的超低分子量肝素的努力，为肝素市场创造了新的成长机会。肝素广泛用于治疗多种疾病，包括深层静脉栓塞症、肺动脉栓塞、急性冠状动脉症候群、心房颤动和心血管手术期间的血液滤过。其应用在整形外科和心血管手术中极为重要，例如髋关节和关节重建。心血管疾病引起的静脉血栓症的发生率不断增加，推动了全球肝素市场的扩张。此外，肝素在心血管手术和整形外科手术等各种外科手术中的使用不断增加，进一步推动了市场成长。然而，一些挑战限制了市场的扩张，包括肝素引起的血小板减少症等副作用。此外，由于它依赖动物源性肝素，因此存在安全性和可得性的担忧，这是一个限制。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 技术分析
  • 价格分析
  • 价值链分析
  • 市场生态系统
  • 贸易分析
  • 供应链分析
  • 案例研究分析
  • 专利分析
  • 客户和购买标准分析
  • 监管环境
  • 创新矩阵
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

肝素市场：依类型

  • 市场概况
  • 低分子肝素
  • 超低分子肝素
  • 普通肝素

肝素市场：依给药途径

  • 市场概况
  • 静脉
  • 皮下的

肝素市场：依原料分类

  • 市场概况
  • 猪
  • 牛
  • 其他的

肝素市场：依应用分类

  • 市场概况
  • 静脉血栓栓塞症
  • 心房颤动
  • 肾功能障碍
  • 冠状动脉疾病
  • 其他的

肝素市场：依最终用途分类

  • 市场概况
  • 门诊
  • 住院病人

肝素市场：按地区分類的规模

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位（2023年）
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率（2023年）

主要企业简介

  • Pfizer Inc.（US）
  • LEO Pharma A/S（Denmark）
  • Dr. Reddy's Laboratories Ltd.（India）
  • Sanofi（France）
  • Aspen Holdings（South Africa）
  • Fresenius SE & Co. KGaA（Germany）
  • B. Braun Medical, Inc.（US）
  • Sandoz（Novartis AG）（Switzerland）
  • Teva Pharmaceutical Industries Ltd.（Israel）
  • Hikma Pharmaceuticals PLC（UK）
  • Amphastar Pharmaceuticals, Inc.（US）
  • Baxter International Inc.（US）
  • Shanghai Fosun Pharmaceutical（Group）Co., Ltd.（China）
  • Bioiberica SAU（Spain）
  • CSL Limited（Australia）
  • Laboratorios ROVI SA（Spain）
  • Opocrin SpA（Italy）
  • Shandong Dongcheng Biochemicals Co., Ltd.（China）
  • Techdow Pharmaceutical Co., Ltd.（China）
  • Syntex SA（Argentina）
  • Jiangxi Haike Biotechnology Co., Ltd.（China）
  • Chemi SpA（Italy）
  • Changzhou Qianhong Bio-pharma Co., Ltd.（China）
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.（China）
  • Hebei Yipin Pharmaceutical Co., Ltd.（China）
  • King-friend Biochemical Pharmaceutical Co., Ltd.（China）
  • Yantai Dongcheng Biochemicals Co., Ltd.（China）
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.（China）
简介目录
Product Code: SQMIG35H2166

Global Heparin Market size was valued at USD 7.32 billion in 2022 and is poised to grow from USD 7.51 billion in 2023 to USD 9.22 billion by 2031, growing at a CAGR of 2.6% during the forecast period (2024-2031).

In August 2022, the FDA approved Momenta Pharmaceuticals, Inc.'s M-Enoxaparin, a generic version of Lovenox developed in collaboration with Sandoz, Novartis AG's generics division. M-Enoxaparin, enhanced with improved technology, is primarily used in major orthopedic procedures such as hip and knee replacements. Recent advances in heparin research, particularly efforts to develop ultra-low molecular weight heparin for chemotherapy, have opened new growth opportunities in the heparin market. Heparin is widely used to treat various conditions including deep vein thrombosis, pulmonary embolism, acute coronary syndrome, atrial fibrillation, and hemofiltration during heart surgery. Its application is crucial in orthopedic surgeries, such as hip and knee replacements, as well as in cardiovascular procedures. The growing incidence of venous thrombosis, driven by cardiovascular diseases, is fueling the expansion of the global heparin market. Additionally, the increasing use of heparin in various surgical operations, including heart and orthopedic surgeries, further drives market growth. However, several challenges limit the market's expansion, including adverse side effects such as heparin-induced thrombocytopenia. Another constraint is the reliance on animal-derived heparin, which raises concerns regarding safety and availability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segmental Analysis

Global Heparin Market is segmented by Type, Route of Administration, Application, end user and region. Based on Type, the market is segmented into Low Molecular Weight Heparin, Ultra-low Molecular Weight Heparin, Unfractionated Heparin. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous. Based on Source, the market is segmented into Porcine, Bovine, Others. Based on Application, the market is segmented into Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, Others. Based on end user, the market is segmented into Outpatient, Inpatient. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Heparin Market

The demand for heparin is rising as coagulation disorders like venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, become more prevalent. VTE is responsible for over 1.2 million deaths annually and is the leading cause of death in Europe, surpassing AIDS, breast and prostate cancer, and traffic accidents combined. Additionally, the global heparin market is expanding due to the increasing incidence of hypertension, often linked to unhealthy lifestyles. The growing rates of heart attacks and strokes present new business opportunities for the heparin industry. According to the American Heart Association (AHA), atrial fibrillation affects 5.3 million Americans, further contributing to the rising demand for heparin. As more patients require treatment for these conditions, the market for heparin is expected to see significant growth.

Restraints in the Global Heparin Market

One of the main challenges hindering the expansion of the heparin market is its adverse side effects. The most common complication associated with heparin use is bleeding, which can occur spontaneously in areas such as the lips, gums, ovaries, uterus, intestines, stomach, and open surgical wounds. Additionally, heparin can trigger a serious condition known as heparin-induced thrombocytopenia (HIT), in which the immune system creates antibodies against the body's platelets, increasing the risk of bleeding. These potential side effects may slow market growth during the forecast period as concerns about safety persist.

Market Trends of the Global Heparin Market

As the use of heparin and other anticoagulant therapies rises, there is an increasing demand for effective reversal agents to mitigate their anticoagulant effects, particularly in emergency situations or during surgical procedures. The need for these agents is critical to ensure patient safety and manage complications that may arise from excessive bleeding. Ongoing research and development efforts are focused on creating new anticoagulant reversal agents, offering an additional growth opportunity for the heparin market. These advancements could enhance the safety profile of anticoagulant therapies and further drive market expansion by addressing a key medical need.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Trade Analysis
  • Supply chain Analysis
  • Case study Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Heparin Market by Type

  • Market Overview
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Unfractionated Heparin

Heparin Market by Route of Administration

  • Market Overview
  • Intravenous
  • Subcutaneous

Heparin Market by Source

  • Market Overview
  • Porcine
  • Bovine
  • Others

Heparin Market by Application

  • Market Overview
  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Coronary Artery Disease
  • Others

Heparin Market by End-use

  • Market Overview
  • Outpatient
  • Inpatient

Heparin Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LEO Pharma A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aspen Holdings (South Africa)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius SE & Co. KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • B. Braun Medical, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sandoz (Novartis AG) (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amphastar Pharmaceuticals, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioiberica S.A.U. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Limited (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Laboratorios ROVI S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Opocrin S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shandong Dongcheng Biochemicals Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Techdow Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Syntex S.A. (Argentina)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jiangxi Haike Biotechnology Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Chemi S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Changzhou Qianhong Bio-pharma Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hebei Yipin Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • King-friend Biochemical Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Yantai Dongcheng Biochemicals Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments